New: FCF Assistant

We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.

FCF funded projects

SInce 2010, FCF has awarded over $25.7 million in grants for research into fibrolamellar carcinoma. Following are details about each of the efforts that FCF has funded through its grant program.

Each grant award includes a brief summary of the project, its status (active or completed), the institution(s) that received the grant, the year of origination, the principal investigator, and the length of the grant commitment.

FCF’s most recent grant awards are listed first.

Each item in this list links to a dedicated page that contains the authoritative details for that item.
Dissecting and Harnessing SIK Tumor Suppressor Function in FLC Massachusetts General Hospital | 2025
View full details →
Uncovering the immunopeptidome of fibrolamellar cancer to expand the target repertoire for T cell-based immunotherapy developmentUniversity Hospital Tübingen | 2025
View full details →
Cellular and in vivo evaluation of DNAJ-PKAc modulator actionUniversity of California at San Francisco | 2025
View full details →
Developing Precision Therapies for of Fibrolamellar Carcinoma (FLC)University of North Carolina | 2025
View full details →
Investigating SLC16A14 in novel models of DNAJB1-PRKACA fusion driven cancerUniversity of Wisconsin | 2025
View full details →
Biochemical and functional characterization of DNAJ-PKAc modulatorsUniversity of Washington | 2025
View full details →
Fibrolamellar Carcinoma Cell Line Derivation and CharacterizationMassachusetts General Hospital | 2025
View full details →
Development and implementation of 3D in vitro fibrolamellar carcinoma tumor modelsOhio State University | 2025
View full details →
DT2216 in Combination with Irinotecan: A Phase 1 Study with a Phase 2 Feasibility Cohort for Fibrolamellar CarcinomaDialectic Therapeutics | 2025
View full details →
Therapeutic Action of Tumor-Specific Amplitude Modulated Radio Frequency Electromagnetic Fields in Fibrolamellar CarcinomaWayne State University | 2025
View full details →
A therapeutic cancer vaccine plus ipilimumab and nivolumab for fibrolamellar hepatocellular carcinoma (FLC)Johns Hopkins University | 2025
View full details →
The Metabolic Implications and Targetability of Mitochondrial Calcium Signaling in FLCUniversity of Washington | 2025
View full details →
Spatially resolving the tumor microenvironment of fibrolamellar carcinomaCornell University | 2025
View full details →
FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patientsUniversity Hospital Tübingen | 2024
View full details →
FLC Research Data InitiativeVelsera | 2024
View full details →
Targeting CDK7 in Fibrolamellar Carcinoma (FLC)University of Wisconsin | 2024
View full details →
X-Chem collaborative effortX-Chem | 2024
View full details →
How fibrolamellar carcinoma differs from hepatocellular carcinoma in children – Creation of a multi-institutional database including central pathologic reviewCincinnati Children's Hospital Medical Center | 2023
View full details →
Molecular therapies for fibrolamellar carcinoma (FLC) – continuationUniversity of Washington | 2023
View full details →
Exploiting a Critical Vulnerability to Glutamine Antimetabolite Therapy in Fibrolamellar Hepatocellular Carcinoma (FLC)Johns Hopkins University and Dracen Pharmaceuticals | 2023
View full details →
CRISPR-engineering of human liver organoids to study fibrolamellar carcinomaPrincess Maxima Center for Pediatric Oncology | 2023
View full details →
Development of pre-clinical murine models for fibrolamellar hepatocellular carcinomaStanford University | 2023
View full details →
Development and Characterization of Patient-derived Models of Fibrolamellar CarcinomaFred Hutchinson Cancer Center | 2023
View full details →
Therapeutic modulation of tumor-infiltrating T cell function in fibrolamellar carcinomaUniversity of Washington | 2023
View full details →
Selective translational inhibition as a treatment strategy for fibrolamellar liver cancerUniversity of California at San Francisco | 2023
View full details →
Clinical trial protocol developmentJohns Hopkins University | 2022
View full details →
Elucidation of nuclear-mitochondrial signaling by DNAJ-PKAc to define targeted vulnerabilities in FLCMassachusetts General Hospital | 2022
View full details →
Characterization of mitochondria alterations and their functional consequences in fibrolamellar carcinoma (FLC) and FLC-like BAP1 hepatocellular carcinomaInserm, Paris, France | 2022
View full details →
Novel synergistic combination therapy in fibrolamellar carcinomaUniversity of Wisconsin | 2022
View full details →
Development of a human-derived liver progenitor cell line with DNAJB1-PRKACA fusion gene and characterization of mitochondrial dynamics in fibrolamellar carcinomaBoston Children’s Hospital | 2022
View full details →
Multicenter consortium to define the single-cell activity landscape of fibrolamellar carcinomaCornell University, Johns Hopkins University and St. Jude Children's Research Hospital | 2022
View full details →
Defining the potential of DNAJB1-PRKACA fusion-specific T cells across human populationsSt. Jude Children's Research Hospital | 2022
View full details →
Disruption of PKA RIα phase separation by the oncogenic fusion protein in FLCUniversity of California at San Diego | 2021
View full details →
Defining incidence of fibrolamellar carcinoma through computational analysis of multiple data typesUniversity of California at San Francisco | 2021
View full details →
Molecular therapies for fibrolamellar carcinoma (FLC) – extensionUniversity of Washington | 2021
View full details →
CRISPR-engineering of human liver organoids to study fibrolamellar carcinomaPrincess Maxima Center for Pediatric Oncology | 2021
View full details →
A gene editing approach to develop new and effective models for FLCUniversity of Wisconsin | 2021
View full details →
Development and validation of an orthotopic, syngeneic, mouse model for fibrolamellar hepatocellular carcinomaJohns Hopkins University | 2021
View full details →
Liquid Biopsy for Active Surveillance of Fibrolamellar Hepatocellular CarcinomaUniversity of Vermont | 2021
View full details →
DNAJB1-PKAc-β-catenin-ALCD-dependent activation of cancer genes plays an essential role in fibrolamellar hepatocellular carcinomaCincinnati Children’s Hospital Medical Center | 2020
View full details →
Identifying therapeutic vulnerabilities in fibrolamellar carcinomaCornell University | 2020
View full details →
Cancer Research Institute (CRI) fellowship program – renewalCancer Research Institute | 2020
View full details →
A phase I/II study of nivolumab plus 5-fluorouracil plus interferon-α2b for unresectable fibrolamellar hepatocellular carcinomaMD Anderson Cancer Center | 2020
View full details →
Creating a fibrolamellar cancer dependency mapBroad Institute of MIT and Harvard | 2020
View full details →
Modulating stromal-immune cell interactions to activate anti-tumor immunity to fibrolamellar carcinomaUniversity of Washington | 2020
View full details →
Fibrolamellar carcinoma model development and analysisMassachusetts General Hospital | 2020
View full details →
Development of a human-derived liver progenitor cell line with DNAJB1-PRKACA fusion geneBoston Children’s Hospital | 2019
View full details →
Expansion conditions for fibrolamellar carcinoma (FLC) organoidsUniversity of North Carolina | 2019
View full details →
Retinoic acid-induced loss of DNAJB1-PRKACA fusion protein expressionCornell University | 2019
View full details →
Targeting DNAJB1-PRKACA driven signaling dependencies in FLCUniversity of California at San Francisco, Massachusetts General Hospital | 2019
View full details →
A Pilot Study of a DNAJB1-PRKACA fusion kinase vaccine combined with nivolumab and ipilimumab for patients with fibrolamellar carcinoma (FLC)Johns Hopkins University | 2019
View full details →
Molecular therapies for fibrolamellar carcinoma (FLC)University of Washington | 2019
View full details →
Micro RNAs and long non-coding RNAs role in fibrolamellar and evaluation of RNA-based therapeuticsCornell University | 2017
View full details →
Therapeutic innovations in fibrolamellar cancerUniversity of Washington | 2017
View full details →
Hedgehog and YAP signaling in fibrolamellar carcinoma: tumor-stroma crosstalk and the cancer stem cell nicheDuke University School of Medicine | 2017
View full details →
Characterizing enzyme inhibition of the DnaJPKAc chimeric protein derived from fibrolamellar hepatocellular carcinomasUniversity of Vermont | 2016
View full details →
Flipping the switch on PKA: synthetic lethal approaches to block PKA-driven tumor growth in fibrolamellar liver cancerUniversity of California at San Francisco, Massachusetts General Hospital | 2016
View full details →
Developing therapeutics for fibrolamellar hepatocellular carcinomaRockefeller University | 2016
View full details →
Pre-clinical studies of the interactions of the immune system with FL-HCCUniversity of California at San Francisco | 2016
View full details →
Investigating immune checkpoint biomarkers in tissue and peripheral blood of patients with fibrolamellar hepatocellular carcinomaJohns Hopkins University | 2016
View full details →
T cell immunotherapy in fibrolamellar cancerUniversity of Washington | 2016
View full details →
Role of the innate immune system in fibrolamellar hepatocellular carcinoma (FL-HCC) using zebrafish as a model systemUniversity of Wisconsin | 2016
View full details →
Developing pre-clinical models for fibrolamellar FL-HCC: therapeutic target identification and testingStanford University | 2016
View full details →
Kinase fusion function investigationMayo Clinic | 2016
View full details →
Cancer Research Institute (CRI) fellowship programCancer Research Institute | 2016
View full details →
Generation of T cells with specificity to FLC’s chimeric fusionJohns Hopkins University | 2015
View full details →
Validating the RNA signature of fibrolamellar hepatocellular carcinomaUniversity of North Carolina | 2015
View full details →
Sequential related donor partial liver followed by bone marrow transplantation for treatment of extensive, liver-confined fibrolamellar hepatocellular carcinoma (FL-HCC)Johns Hopkins University | 2014
View full details →
Iodine transporter researchYale University | 2014
View full details →
High priority FLC investigationsRockefeller University | 2013
View full details →
Creation of Fibrolamellar Tissue Repository at The Rockefeller UniversityRockefeller University | 2013
View full details →
Genomic initiative on Fibrolamellar Hepatocellular CarcinomaRockefeller University | 2013
View full details →
Molecular analysis of FLC tumorsMemorial Sloan Kettering Cancer Center | 2013
View full details →
Analysis of the immunology, imaging and cell biology of fibrolamellar – continuedRockefeller University | 2011
View full details →
Everolimus clinical trialMemorial Sloan Kettering Cancer Center | 2010
View full details →
Analysis of the immunology, imaging and cell biology of fibrolamellarRockefeller University | 2010
View full details →
Establishment of FLC cell line and xenograft from FLC tumor samplesUniversity of British Columbia | 2010
View full details →
Developmental biology of fibrolamellar hepatocellular carcinomaUniversity of North Carolina | 2010
View full details →
International Cancer Alliance for Research and Education (ICARE) research effort coordinationICARE | 2010
View full details →
Blood markers for fibrolamellarJohns Hopkins University | 2010
View full details →
Bioinformatic and molecular analysis of FLCICARE | 2010
View full details →
View of the 2022 Fibrolamellar Patient & Research Summit